BTMD

biote Corp.

$1.08

-2.70%
SectorHealthcareIndustryMedical Care FacilitiesCountryUnited States

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to facilitate ordering and inventory control; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.

Source: Yahoo Finance
AI summary

Price & performance

1M-6.1%
3M-29.9%
YTD-56.3%
1Y-56.1%
52-week range—
Beta1.38
Full chart and returns against a benchmark

Q-Score

48/ 100

Quality against peers; 50 is the peer median.

Growth29
Risk44
Performance25
Valuation93
Profitability66
Leverage56
Sentiment27
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$192.2M-2.5%
Net income$27M+756.7%
Net margin14.1%+12.5 pts
Historical fundamentals

Red flags in filings

1active red flag
Material weakness in controlsMar 13, 2026
Filings, findings and the timeline

Revenue exposure

1%of revenue from outside the US
United States99%
Non Us1%
Regions, segments, customers and suppliers

Valuation

BTMDIndustryP/E—12.66P/S0.201.15EV/EBITDA11.4613.41P/B—7.42PEG—0.49
Dividend yield3.19%
Every valuation metric

Earnings

Nov 4next report
EPS estimate$0.04
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate